Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | KDM6B | O15054 | 1/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 1.00 |
| ▸ | KDM4A | O75164 | 1/20 | 1.00 |
| ▸ | KDM4B | O94953 | 1/20 | 1.00 |
| ▸ | KDM5A | P29375 | 1/20 | 1.00 |
| ▸ | KDM5C | P41229 | 1/20 | 1.00 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 1.00 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382353 | 1.00 | KDM4E (1.00) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL17670545 | 1.00 | KDM4E (1.00) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL17670544 | 1.00 | KDM4E (1.00) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL20214000 | 1.00 | KDM4E (1.00) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL30539398 | 0.92 | KDM4E (0.85) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL4926318 | 0.84 | KDM4E (0.72) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL20101080 | 0.84 | KDM4E (0.72) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL18159120 | 0.84 | KDM4E (0.73) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL31237795 | 0.81 | KDM4E (0.68) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL20101021 | 0.79 | KDM4E (0.65) | KDM4EKDM6BTET3KDM4AKDM4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| US-20240392253-A1 | COMPOSITION FOR INDUCTION OF PLURIPOTENT STEM CELL | GMU MEDICAL DRUG DEVELOPMENT CO., LTD. (CN) | 2024-11-28 | — | — | US | claimed |
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | claimed |
| US-11873494-B2 | Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia | UNIVERSITY OF MASSACHUSETTS (US) | 2024-01-16 | — | — | US | claimed |
| CN-117159542-A | Application of JIB-04 in preparing medicine for treating pulmonary alveolar proteinosis | 厦门大学 | 2023-12-05 | — | — | CN | claimed |
| CN-117088808-A | Antifungal compound and application thereof | 中国人民解放军海军军医大学 | 2023-11-21 | — | — | CN | claimed |
| US-20230285498-A1 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE | 2023-09-14 | — | — | US | claimed |
| US-20230255951-A1 | USE OF JUMONJI C DEMETHYLASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY RESISTANCE AND RADIORESISTANCE IN CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-08-17 | — | — | US | claimed |
| CN-113521291-B | Application of ZNF143-MDIG-CDC6 axis in hepatocellular carcinoma | 上海市肿瘤研究所 | 2022-11-29 | — | — | CN | claimed |
| US-11497740-B2 | Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-15 | — | — | US | claimed |
| US-11458122-B2 | Methods for treating diseases and nerve injuries | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-10-04 | — | — | US | claimed |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | claimed |
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2022-06-16 | — | — | US | claimed |
| US-11311538-B2 | Compositions and methods for targeting cancers | YALE UNIVERSITY (US) | 2022-04-26 | — | — | US | claimed |
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
| US-20220042023-A1 | Genetic and Pharmacological Transcriptional Upregulation of the Repressed FXN Gene as a Therapeutic Strategy for Friedreich Ataxia | UNIVERSITY OF MASSACHUSETTS | 2022-02-10 | — | — | US | claimed |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-113966326-A | Water soluble adjuvants | 大日本住友制药株式会社 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | GMFG, HGF, BDNF | KDM4E 4101/4885KDM6B 3295/4885TET3 4645/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | KDM4E 4709/4885KDM6B 3478/4885TET3 2139/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | KDM4E 4155/4885KDM6B 3099/4885TET3 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.